Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

NCT03713320 is registered in ClinicalTrials.gov with miRagen Therapeutics, Inc. as lead sponsor.

NCT NCT03713320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03713320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Lead sponsor
miRagen Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 2, 2019
Completion date
December 1, 2020
Enrollment
37 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma/mycosis fungoides